ArticleAntimicrobial agents and chemotherapy2019
Population Pharmacokinetics and Dosing Optimization of Linezolid in Pediatric Patients.
Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Safety and clinical efficacy of linezolid in children: a systematic review and meta-analysis.World journal of pediatrics : WJP · 2023Pooled it
- Pharmacokinetics of Commonly Used Medications in Children Receiving Continuous Renal Replacement Therapy: A Systematic Review of Current Literature.Clinical pharmacokinetics · 2022Pooled it
- Reflections on the Theoretical Prerequisites for Initial Oral Antibiotic Treatment for Paediatric Bone and Joint Infections: A Narrative Review.Antibiotics (Basel, Switzerland) · 2026Review
- Machine learning combined with population pharmacokinetics: a hybrid model for predicting the plasma concentration of linezolid in critically ill pediatric patients.Frontiers in pharmacology · 2026Article
- Methicillin-resistantThe Lancet regional health. Western Pacific · 2025Review
- Population pharmacokinetics and clinical assessment of linezolid in pediatric bacterial infections.Antimicrobial agents and chemotherapy · 2025Article
- Therapeutic drug monitoring of linezolid in Chinese premature neonates: a population pharmacokinetic analysis and dosage optimization.Antimicrobial agents and chemotherapy · 2024Article
- Silicone allergy manifestation in pediatric ventriculoperitoneal shunting: navigating diagnostic challenges and customizing therapeutic approaches. Illustrative case.Journal of neurosurgery. Case lessons · 2024Article
- Population Pharmacokinetics and Dosage Optimization of Linezolid in Critically Ill Pediatric Patients.Antimicrobial agents and chemotherapy · 2023Article
- A Review of Population Pharmacokinetic Analyses of Linezolid.Clinical pharmacokinetics · 2022Review
- Enteral Linezolid as an Effective Option to Treat an Extremely Preterm Infant withChildren (Basel, Switzerland) · 2022Article
- Relationship Between Linezolid Exposure and the Typical Clinical Laboratory Safety and Bacterial Clearance in Chinese Pediatric Patients.Frontiers in pharmacology · 2022Article
- Dosage Strategy of Linezolid According to the Trough Concentration Target and Renal Function in Chinese Critically Ill Patients.Frontiers in pharmacology · 2022Article
- Population Pharmacokinetic Study of Cefathiamidine in Infants With Augmented Renal Clearance.Frontiers in pharmacology · 2021Article
- Staphylococcal meningitis therapy with linezolid in a young infant: efficacy, CSF levels and side effects.Italian journal of pediatrics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Linezolid is a synthetic antibiotic very effective in the treatment of infections caused by Gram-positive pathogens. Although the clinical application of linezolid in children has increased progressively, data on linezolid pharmacokinetics in pediatric patients are very limited. The aim of this study was to develop a population pharmacokinetic model for linezolid in children and optimize the dosing strategy in order to improve therapeutic efficacy. We performed a prospective pharmacokinetic study of pediatric patients aged 0 to 12 years. The population pharmacokinetic model was developed using the NONMEM program. Goodness-of-fit plots, nonparametric bootstrap analysis, normalized prediction distribution errors, and a visual predictive check were employed to evaluate the final model. The dosing regimen was optimized based on the final model. The pharmacokinetic data from 112 pediatric patients ages 0.03 to 11.9 years were analyzed. The pharmacokinetics could best be described by a one-compartment model with first-order elimination along with body weight and the estimated glomerular filtration rate as significant covariates. Simulations demonstrated that the currently approved dosage of 10 mg/kg of body weight every 8 h (q8h) would lead to a high risk of underdosing for children in the presence of bacteria with MICs of ≥2 mg/liter. To reach the pharmacokinetic target, an elevated dosage of 15 or 20 mg/kg q8h may be required for them. The population pharmacokinetics of linezolid were characterized in pediatric patients, and simulations provide an evidence-based approach for linezolid dosage individualization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.